Fastest Growing Stocks
XOMA is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
XOMA ROYALTY CORPORATION (XOMA) Stock Price & Overview
NASDAQ:XOMA • US98419J2069
Current stock price
41.38 USD
+0.44 (+1.07%)
At close:
41.38 USD
0 (0%)
After Hours:
The current stock price of XOMA is 41.38 USD. Today XOMA is up by 1.07%. In the past month the price increased by 25.47%. In the past year, price increased by 70.15%.
XOMA Key Statistics
52-Week Range22.29 - 42.81
Current XOMA stock price positioned within its 52-week range.
1-Month Range33.01 - 42.81
Current XOMA stock price positioned within its 1-month range.
- Market Cap
- 493.25M
- P/E
- 28.34
- Fwd P/E
- 84.52
- EPS (TTM)
- 1.46
- Dividend Yield
- N/A
XOMA Stock Performance
Today
+1.07%
1 Week
+9.18%
1 Month
+25.47%
3 Months
+61.26%
Longer-term
6 Months +25.47%
1 Year +70.15%
2 Years +60.45%
3 Years +143.41%
5 Years +40.41%
10 Years +199.86%
XOMA Stock Chart
XOMA Stock Screens
XOMA currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
XOMA is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
Strong Momentum Stocks
XOMA is part of our Strong Momentum Stocks screen, indicating it has an already in confirmed uptrend.
RSI Overbought Stocks
XOMA is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
Bull Flag Stocks
XOMA is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
CAN SLIM Stocks
XOMA is part of our CAN SLIM stock list, indicating it is suited for high growth momentum investing and is a technical leader.
Highest Analyst Upside Stocks
XOMA is part of our highest analyst upside stock list, indicating analysts have a price target way above the current price.
High EPS Growth Stocks
XOMA occurs in our High EPS Growth Stocks screen list, indicating it is profitable, healthy and showing strong recent EPS growth.
Small Cap Growth Stocks
XOMA is part of our Small Cap Growth Stocks list, indicating it is a fast growing small cap stock.
XOMA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to XOMA. When comparing the yearly performance of all stocks, XOMA is one of the better performing stocks in the market, outperforming 92.52% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
XOMA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to XOMA. XOMA has an average financial health and profitability rating.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
XOMA Earnings
On April 30, 2026 XOMA reported an EPS of 0.26 and a revenue of 13.76M. The company beat EPS expectations (264.45% surprise) and beat revenue expectations (22.07% surprise).
Next Earnings DateAug 11, 2026
Last Earnings DateApr 30, 2026
PeriodQ4 / 2025
EPS Reported$0.26
Revenue Reported13.757M
EPS Surprise 264.45%
Revenue Surprise 22.07%
XOMA Forecast & Estimates
11 analysts have analysed XOMA and the average price target is 67.07 USD. This implies a price increase of 62.07% is expected in the next year compared to the current price of 41.38.
For the next year, analysts expect an EPS growth of -66.47% and a revenue growth 28.91% for XOMA
Analysts
Analysts81.82
Price Target67.07 (62.08%)
EPS Next Y-66.47%
Revenue Next Year28.91%
XOMA Index Membership
XOMA is currently included in the following stock indexes tracked on ChartMill.
XOMA Financial Highlights
Over the last trailing twelve months XOMA reported a non-GAAP Earnings per Share(EPS) of 1.46. The EPS increased by 170.87% compared to the year before.
Income Statements
Revenue(TTM)52.15M
Net Income(TTM)18.53M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 35.54% | ||
| ROA | 6.8% | ||
| ROE | 17.83% | ||
| Debt/Equity | 0.93 |
Chartmill High Growth Momentum
EPS Q2Q%157.78%
Sales Q2Q%57.87%
EPS 1Y (TTM)170.87%
Revenue 1Y (TTM)73.96%
XOMA Ownership
Ownership
Inst Owners73.82%
Shares11.92M
Float11.44M
Ins Owners3.97%
Short Float %10.73%
Short Ratio6.34
XOMA Industry Overview
XOMA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
XOMA Latest News, Press Relases and Analysis
11 days ago - By: Chartmill
XOMA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XOMA
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Company Info
IPO: 1986-06-06
XOMA ROYALTY CORPORATION
2200 Powell Street, Suite 310
Emeryville CALIFORNIA 94608 US
CEO: James Neal
Employees: 13
Phone: 15102047200
XOMA ROYALTY CORPORATION / XOMA FAQ
Can you describe the business of XOMA ROYALTY CORPORATION?
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
What is the current price of XOMA stock?
The current stock price of XOMA is 41.38 USD. The price increased by 1.07% in the last trading session.
What is the dividend status of XOMA ROYALTY CORPORATION?
XOMA does not pay a dividend.
What is the ChartMill rating of XOMA ROYALTY CORPORATION stock?
XOMA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in XOMA ROYALTY CORPORATION be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on XOMA.
Is XOMA ROYALTY CORPORATION (XOMA) expected to grow?
The Revenue of XOMA ROYALTY CORPORATION (XOMA) is expected to grow by 28.91% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for XOMA ROYALTY CORPORATION?
XOMA ROYALTY CORPORATION (XOMA) has a market capitalization of 493.25M USD. This makes XOMA a Small Cap stock.